C4 Therapeutics : Corporate Presentation – March 2024

Protein degraded. Disease targeted. Lives transformed.

March 2024

Forward-looking Statements and Intellectual Property

Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward- looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward- looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology

and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among

the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The forward- looking statements included in this presentation are subject to a variety of risks and uncertainties, including those set forth in our most

recent and future filings with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated

in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.

Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols ®, SM and , but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to.

© 2024 C4 Therapeutics, Inc.

2

C4T is a Recognized Leader in Delivering on the Promise of Targeted Protein Degradation

WORLD-CLASS DEGRADER PLATFORM

Our Mission

To deliver on the promise

of targeted protein

degradation science to create a new generation of medicines that transform patients' lives

Robust patent portfolio of novel cereblon binders; Demonstrated ability to design orally

bioavailable, catalytically efficient degraders

RIGOROUS TARGET SELECTION

Focus on targets with a clear degrader

rationale

BROAD DEGRADER APPROACH

MonoDAC and BiDAC degraders, as well as degrader-antibodyconjugates

CLINICAL PIPELINE

Oncology degraders against targets of high unmet need

© 2024 C4 Therapeutics, Inc.

3

We Have Designed and Advanced Degraders into the Clinic across a Range of Target Classes, Resulting in Robust Target Degradation

Interrogated Diverse	Attained
Target Classes	IND Clearance

Discovered degraders and advanced

4 INDs against a transcription factor, a chromatin modifier, and two kinases

1. Evaluated three programs in the clinic as of 1/9/2024 Investigational New Drug Application (IND)

Achieved Desirable	Degraded Target as
Drug-like Properties	Predicted

To date, we have evaluated

3 programs in the clinic1, with each demonstrating robust target degradation in patients

© 2024 C4 Therapeutics, Inc.

4

Prioritized Pipeline to Deliver Near-Term Value

Program	Target	Indications		Discovery		Preclinical	Early phase	Late phase	Rights
		development	development
		Multiple Myeloma &
CFT7455	IKZF1/3	Non-Hodgkin's
		Lymphoma
CFT1946	BRAF	V600X Mutant
V600X	Cancers
CFT89191	EGFR	Non-Small Cell Lung
L858R	Cancers
Undisclosed Discovery	Various Cancers
Stage Programs
		Autoimmune &			2 targets
		Cancer
Undisclosed	Autoimmune &			2 targets
Neurological
Collaboration Programs
Cancer		1 target
		Cancer		2 targets
1. License and Collaboration Agreement with Betta Pharmaceuticals for the development and commercialization in Greater China
			© 2024 C4 Therapeutics, Inc.			5

degraders against critical oncogenic proteins

2024 Milestones: Advancing High-potential Programs

				Multiple Value Inflection Points over Next 12 Months
				with Sufficient Runway (into 20271) Beyond These Milestones
	CFT7455	•	2H	2024: Present updated data from Phase 1 dose escalation +dex trial in R/R MM
	IKZF1/3	• 2H	2024: Present data from Phase 1 dose escalation monotherapy trial in R/R NHL
	•	By YE 2024: Complete Phase 1 dose exploration in R/R MM and R/R NHL

CFT1946

BRAF

V600X

CFT8919

EGFR

L858R

• 2Q 2024: Present preclinical data demonstrating differentiated activity in BRAF V600X melanoma, CRC, NSCLC, and brain metastasis models at AACR
• 2H 2024: Present data from Phase 1 dose escalation trial in melanoma, CRC, NSCLC, and other BRAF V600X cancers
• 2024: Support trial start-up activities related to Betta's Phase 1 dose escalation trial in China

Discovery

• 1Q 2024: Collaboration with Merck KGaA, Darmstadt, Germany to discover two targeted protein

• 2024: Deliver development candidate to collaboration partner

1. Cash, cash equivalents and marketable securities as of December 31, 2023, together with cash received in January 2024, results in a proforma balance of approximately $330 million Dexamethasone (dex); Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC); Year-end (YE)

© 2024 C4 Therapeutics, Inc.

6

CFT7455

Targeting IKZF1/3

Multiple Myeloma (MM)

• Non-Hodgkin'sLymphoma (NHL)

IKZF1/3 Degradation Drives Three Distinct Areas of Hematopoietic Biology; Degrading IKZF1/3 is a Validated Therapeutic Strategy in MM and NHL

IKZF1 / IKZF3

Transcription Factors

Drive MM and NHL Cell	Activate Fully	Regulate Hematopoietic
Growth and Survival	Differentiated T-cells	Stem Cell Differentiation
	CD8+	Hematopoietic
		Stem Cell

MM and

NHL Cells

Activated CD8+

Neutrophil

Consequences of IKZF1/3 Degradation:

• MM and NHL Cell Death

• T-cell Activation

• On-target Neutropenia

Ikaros Family Zinc Finger proteins 1 and 3 (IKZF1/3); Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL)

© 2024 C4 Therapeutics, Inc

8

CFT7455 Phase 1 Dose Escalation Trial's Goal is to Define the Safety Profile and Identify Signs of Anti-Tumor Activity in R/R MM and R/R NHL

Phase 1 Dose Escalation Trial

R/R MM

Monotherapy

Dosing: QD

21 days on/7 days off

N=5

Status: Complete

R/R MM	R/R MM	R/R NHL
Monotherapy	Dex Combo	Monotherapy
Dosing: MWF & QD	Dosing: MWF & QD	Dosing: MWF & QD
14 days on/14 days	14 days on/14 days	14 days on/14 days
off	off	off
N=22	N = ~20	N = ~20
Status: Complete	Status: Ongoing	Status: Ongoing

Endpoints

Primary:

• Safety and tolerability
• Determine the maximum tolerated doses

Secondary:

• Estimate anti-tumor activity
• Assess PK

Exploratory:

• Characterize target engagement
• Assess kinetics, depth, recovery and consistency of target engagement
• Assess immunomodulation

Pharmacokinetic (PK); Monday, Wednesday, Friday dosing (MWF); once daily (QD); Relapsed refractory multiple myeloma (R/R MM);

Relapsed refractory non-Hodgkin's lymphoma (R/R NHL); Dexamethasone (Dex)

© 2024 C4 Therapeutics, Inc

9

Schedule Adjustment Yielding Expected Results for CFT7455 as a Potential MM Therapy

+

CFT7455 is a potential

treatment for multi-

refractory MM patients

with the ability to move

Established Safety Profile	Demonstrated
and Dosing Schedule	Monotherapy Activity

Promising Responses with CFT7455 + Dexamethasone

into earlier lines with

numerous combination

• CFT7455 is well tolerated with no DLTs resulting in treatment discontinuations
• The 14 days on/14 days off schedule is optimal

• Anti-myelomaactivity and immunomodulatory effects observed at well tolerated doses
• Opportunity in combination with novel MM agents for early-line patients and as a maintenance therapy option

• Multiple patients achieved IMWG responses at low doses with best responses in patients refractory to BCMA therapies
• Opportunity in combination with dexamethasone for multi-refractory patients

opportunities

Dose Limiting Toxicities (DLTs); Multiple myeloma (MM); B cell maturation antigen (BCMA); International Myeloma Working Group (IMWG) Source: C4T data on file as 11/28/2023

© 2024 C4 Therapeutics, Inc.

10